Fresenius SE & Co KGaA (FRA:FRE) Given a €52.00 Price Target at Goldman Sachs Group

Fresenius SE & Co KGaA (FRA:FRE) has been given a €52.00 ($60.47) price target by stock analysts at Goldman Sachs Group in a report released on Wednesday, Borsen Zeitung reports. The firm currently has a “buy” rating on the stock. Goldman Sachs Group’s price objective would suggest a potential upside of 14.66% from the stock’s previous close.

A number of other analysts have also recently issued reports on FRE. Morgan Stanley set a €50.00 ($58.14) target price on Fresenius SE & Co KGaA and gave the stock a “neutral” rating in a research note on Thursday, May 16th. Independent Research set a €53.00 ($61.63) price target on Fresenius SE & Co KGaA and gave the stock a “neutral” rating in a research report on Friday, May 3rd. Barclays set a €52.00 ($60.47) price target on Fresenius SE & Co KGaA and gave the stock a “neutral” rating in a research report on Tuesday, April 30th. UBS Group set a €46.00 ($53.49) price target on Fresenius SE & Co KGaA and gave the stock a “neutral” rating in a research report on Thursday, May 9th. Finally, Deutsche Bank set a €65.00 ($75.58) price target on Fresenius SE & Co KGaA and gave the stock a “buy” rating in a research report on Tuesday, April 9th. Ten equities research analysts have rated the stock with a hold rating and ten have given a buy rating to the stock. Fresenius SE & Co KGaA currently has an average rating of “Buy” and a consensus target price of €59.55 ($69.24).

FRA FRE traded down €1.42 ($1.65) during trading hours on Wednesday, reaching €45.35 ($52.73). 1,101,289 shares of the company’s stock were exchanged. Fresenius SE & Co KGaA has a one year low of €60.16 ($69.95) and a one year high of €80.00 ($93.02).

Fresenius SE & Co KGaA Company Profile

Fresenius SE & Co KGaA, a health care group, provides products and services for dialysis, hospitals, and outpatient medical care worldwide. The company operates through Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed segments. The Fresenius Medical Care segment offers products for patients with chronic kidney failure.

Featured Article: How much can an individual set aside as a catch-up contribution?

Analyst Recommendations for Fresenius SE & Co KGaA (FRA:FRE)

Receive News & Ratings for Fresenius SE & Co KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fresenius SE & Co KGaA and related companies with MarketBeat.com's FREE daily email newsletter.